Company intelligence / Profile preview
Renovaro Inc.
Los Angeles, California, United Statesrenovarogroup.com ↗
- Ownership
- Public · RENB
- Employees
- ~25
- Development stage
- Preclinical
01
Overview
Renovaro is a pre-clinical stage biotechnology company developing genetically modified allogeneic dendritic cell therapeutic vaccines and an AI platform for early cancer detection. The company has not yet reported clinical results.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Cell therapyGene therapyImmunotherapyDendritic cell-based therapy
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Nebul
Beyond the preview
Go deeper on Renovaro Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renovaro Inc..